OAK BROOK, ILL. — PureCircle has received a “no objection” letter from the U.S. Food and Drug Administration for the use of PureCircle’s SG95 product as a food and beverage ingredient in the United States. The clearance enables PureCircle to offer a wider and more flexible array of stevia solutions to manufacturers in the U.S. market, according to the company.
Along with seven previously approved steviol glycosides found in the stevia plant, SG95 includes two new steviol glycosides, Rebaudioside D and Rebaudioside F, both of which are receiving GRAS no-objection status from the F.D.A. for the first time. PureCircle said the product ideally is suited for applications formulated with both sugar and SG95 to achieve a low-cost solution to partial sugar and calorie reduction.
“The launch of SG95 is a very exciting development for PureCircle in the United States with considerable future potential in global markets,” said Magomet Malsagov, chief executive officer and managing director of PureCircle. “Expanded use of sweet glycosides from the stevia plant provides both formulation and economic benefits to our customers. Our Reb A 97 continues to play a major role in our portfolio, particularly as our investments yield continued efficiencies that will be shared with our customers. Now, SG95 will provide an additional compelling product today in many applications. We are proud to continue to be at the forefront of innovation to help mainstream a better sweet choice for consumers.”